Quince Therapeutics, Inc. Operating Lease, Expense
Quince Therapeutics, Inc. (QNCX) reported Operating Lease, Expense of $43.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-14
- Quince Therapeutics, Inc. operating lease, expense for the quarter ending 2026-06-30 was $43.00K, a 13.16% increase year-over-year.
- Quince Therapeutics, Inc. operating lease, expense for the quarter ending 2026-03-31 was $37.00K, a 5.71% increase year-over-year.
- Quince Therapeutics, Inc. operating lease, expense for the quarter ending 2025-12-31 was $100.00K.
- Quince Therapeutics, Inc. operating lease, expense for the quarter ending 2025-09-30 was $38.00K, a 8.57% increase year-over-year.
- Quince Therapeutics, Inc. operating lease, expense for fiscal 2025 was $200.00K, a 100.00% increase from fiscal 2024.
- Quince Therapeutics, Inc. operating lease, expense for fiscal 2024 was $100.00K, a 75.00% decline from fiscal 2023.
- Quince Therapeutics, Inc. operating lease, expense for fiscal 2023 was $400.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 6 month as first filed | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $43.00K 10-Q · filed 2026-08-14 | $80.00K 10-Q · filed 2026-08-14 | $180.00K derived: sum of 3 quarters · filed 2026-08-14 | $218.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $37.00K 10-Q · filed 2026-05-11 | $137.00K derived: sum of 2 quarters · filed 2026-05-11 | $175.00K derived: sum of 3 quarters · filed 2026-05-11 | $213.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $138.00K derived: sum of 2 quarters · filed 2026-04-10 | $176.00K derived: sum of 3 quarters · filed 2026-08-14 | $200.00K 10-K · filed 2026-04-10 | ||
| 2025-09-30 | $38.00K 10-Q · filed 2025-11-12 | $76.00K derived: sum of 2 quarters · filed 2026-08-14 | $100.00K 10-Q · filed 2025-11-12 | $111.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $38.00K 10-Q · filed 2026-08-14 | $76.00K 10-Q · filed 2026-08-14 | $73.00K derived: sum of 3 quarters · filed 2026-08-14 | $108.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $35.00K 10-Q · filed 2026-05-11 | $35.00K derived: sum of 2 quarters · filed 2026-05-11 | $70.00K derived: sum of 3 quarters · filed 2026-05-11 | $104.00K derived: sum of 4 quarters · filed 2026-05-11 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $35.00K derived: sum of 2 quarters · filed 2026-04-10 | $69.00K derived: sum of 3 quarters · filed 2026-04-10 | $100.00K 10-K · filed 2026-04-10 | ||
| 2024-09-30 | $35.00K 10-Q · filed 2025-11-12 | $69.00K derived: sum of 2 quarters · filed 2025-11-12 | $100.00K 10-Q · filed 2025-11-12 | $391.00K derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $34.00K 10-Q · filed 2025-08-11 | $100.00K 10-Q · filed 2024-08-13 | $64.00K 10-Q · filed 2025-08-11 | $100.00K 10-Q · filed 2024-08-13 | $356.00K derived: sum of 3 quarters · filed 2025-08-11 | $356.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $22.00K 10-Q · filed 2025-05-13 | $322.00K derived: sum of 2 quarters · filed 2025-05-13 | $322.00K derived: sum of 3 quarters · filed 2025-05-13 | $422.00K derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $300.00K derived: sum of 2 quarters · filed 2025-03-24 | $400.00K derived: sum of 3 quarters · filed 2025-03-24 | $400.00K 10-K · filed 2025-03-24 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $100.00K derived: sum of 2 quarters · filed 2024-11-13 | $100.00K 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $100.00K 10-Q · filed 2024-08-13 | $100.00K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |